Year in review: Top articles of 2018
It’s been a busy year–with breaking HIV news, innovations in PrEP, an anal health campaign, and more. Here were our top articles in 2018. Did you see them all?
Substance use counselor Jeremy Prillwitz shares what we know about booty bumping, the risks and potential harms, and how to booty bump more safely.
Get an HIV doctor’s answers to your burning questions about undetectable viral load—and what it means for your health and your sex life.
Researchers say that although the two-pronged treatment failed to reduce the viral reservoir, we shouldn’t lose hope that a “kick and kill” strategy might someday be successful.
Liz Highleyman summarizes the PrEP and HIV prevention research presented recently at the domestic HIV conference, CROI, including a new possible PrEP drug, real world PrEP effectiveness, and more.
This week, the FDA granted approval of Gilead Science’s single-table combo pill of bictegravir, emtricitabine, and tenofovir alafenamide named Biktarvy.
Don’t suffer in silence if you’re experiencing sharp, stabbing pain when you bottom or when you poop. Painful paper-cut-like tears in your anal canal happen—they’re called anal fissures—and they’re treatable.
Overall, clinicians recognize the potential benefits of STI prophylaxis, but there’s still uncertainty over whether the protection offered is enough to justify risk of drug resistance, pill fatigue, and other concerns.
You told us—pain during anal sex can be mind-blowing. Here’s what you shared in our anonymous pain & sex survey.
Syringe access programs combat the spread of infectious diseases among people who use injection drugs, improve participant health, and increase linkage to social services including drug treatment.
A case of PrEP failure due to transmitted drug resistance was reported at IDWeek 2018. Chris Hall, MD shares what this means for people currently taking PrEP.